ESMO Open最新文献

{"title":"Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors","authors":"J. Ros ,&nbsp;M.C. de Grandis ,&nbsp;V. Navarro ,&nbsp;I. Baraibar ,&nbsp;F. Salva ,&nbsp;C. Vaghi ,&nbsp;A. Garcia ,&nbsp;A. Alcaraz ,&nbsp;A.M. López ,&nbsp;M. Rodriguez ,&nbsp;C. Salvà ,&nbsp;N. Mulet-Margalef ,&nbsp;J.L. Manzano ,&nbsp;R. Querol ,&nbsp;M. Pampols ,&nbsp;E. Castillo ,&nbsp;A. Vivancos ,&nbsp;J. Tabernero ,&nbsp;E. Elez","doi":"10.1016/j.esmoop.2026.107694","DOIUrl":"10.1016/j.esmoop.2026.107694","url":null,"abstract":"<div><h3>Background</h3><div>The optimal duration of immune checkpoint inhibitor (ICI) treatment in patients with metastatic colorectal cancer (mCRC) with microsatellite instability/mismatch repair deficiency (MSI/dMMR) remains undefined.</div></div><div><h3>Patients and methods</h3><div>We retrospectively analyzed data of 84 patients with MSI/dMMR mCRC treated with ICIs at any line of therapy who discontinued treatment for any reason.</div></div><div><h3>Results</h3><div>After a median follow-up period of 48 months, 51% of patients stopped treatment due to disease progression and 49% discontinued for other reasons, including immune-related adverse events, clinical benefit, protocol completion (2 years), surgery, or pregnancy. Among patients who discontinued without progression, treatment cessation did not negatively impact progression-free survival or overall survival. Patients who achieved radiologic response and stopped without progression rarely relapsed. Liquid biopsy analysis using circulating tumor DNA (ctDNA) was available from 48 patients. Among those who stopped per protocol, nearly 80% had negative ctDNA at discontinuation, with only 7% of them progressing during follow-up. Conversely, among those patients who progressed, 78.3% had positive liquid biopsy results at treatment discontinuation, underscoring the complexity of molecular monitoring.</div></div><div><h3>Conclusions</h3><div>These findings support the safety of early ICI discontinuation (&lt;2 years) in responding patients and suggest that ctDNA may aid in identifying optimal stopping points. However, due to the retrospective design and limited sampling, these results should be interpreted as hypothesis-generating. Prospective studies are required to define the precise role of ctDNA in guiding ICI duration in dMMR/MSI mCRC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 5","pages":"Article 107694"},"PeriodicalIF":8.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147799818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2","authors":"S. Joris ,&nbsp;H. Denys ,&nbsp;J. Collignon ,&nbsp;M. Rasschaert ,&nbsp;D.T. de Roodenbeke ,&nbsp;F.P. Duhoux ,&nbsp;J.L. Canon ,&nbsp;S. Tejpar ,&nbsp;J. Mebis ,&nbsp;L. Decoster ,&nbsp;P. Aftimos ,&nbsp;J. De Grève","doi":"10.1016/j.esmoop.2026.107693","DOIUrl":"10.1016/j.esmoop.2026.107693","url":null,"abstract":"<div><h3>Background</h3><div>Olaparib is registered for use in ovarian, breast, pancreatic and prostate cancers with a <em>BRCA1/2</em> mutation and/or mutations in other homologous recombination deficiency (HRD) genes. HRD gene mutations are also found in other cancer types, and these cancers may also benefit from olaparib therapy. We aimed to evaluate the efficacy of olaparib in advanced cancers harboring a (likely) pathogenic germline or somatic mutation in a gene involved in homologous recombination (HR).</div></div><div><h3>Patients and methods</h3><div>This investigator-initiated, open-label, basket phase II trial evaluates the efficacy of olaparib in patients with advanced tumors harboring HR gene mutations following progression on standard-of-care therapies. Cohorts were stratified based on the presence of either somatic or germline mutations in the same HR-related gene. Although results from the completed cohorts have been previously published, this report presents a case series focusing on cohorts with rare gene alterations.</div></div><div><h3>Results</h3><div>In patients who harbor a tumor mutation in <em>ARID1A</em>, <em>ATR</em>, <em>ATRX</em>, <em>BLM</em>, <em>CDK12</em>, <em>CHEK1</em>, <em>DDR2</em>, <em>ERCC4</em>, <em>FANCE</em>, <em>GEN1</em>, <em>MRE11A</em>, <em>NBN</em>, <em>POLE</em>, <em>RAD21</em>, <em>RAD50</em>, <em>RAD51C</em>, <em>RAD51D</em>, <em>RAD52</em> and <em>SLX4</em>, no responses were observed. In the <em>BAP1</em>, <em>BARD1</em>, <em>BRIP1</em> and <em>PALB2</em> cohorts, objective responses were detected.</div></div><div><h3>Conclusion</h3><div>Olaparib demonstrated meaningful clinical activity across different cancer types with somatic or germline mutations in <em>BAP1</em>, <em>BARD1</em>, <em>BRIP1</em> and <em>PALB2</em>.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 5","pages":"Article 107693"},"PeriodicalIF":8.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147851973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep molecular profiling of biliary tract cancer uncovers novel biological mechanisms and therapeutic opportunities","authors":"F. Nichetti ,&nbsp;P. Hoffmeister ,&nbsp;F. Korell ,&nbsp;J. Huellein ,&nbsp;S. Uhrig ,&nbsp;M. Rübsam ,&nbsp;M. Schwab ,&nbsp;M.-V. Teleanu ,&nbsp;M. Jenzer ,&nbsp;S. Kreutzfeld ,&nbsp;P. Horak ,&nbsp;P. Konietzke ,&nbsp;H. Glimm ,&nbsp;C. Heining ,&nbsp;D. Rieke ,&nbsp;T. Kindler ,&nbsp;C. Springfeld ,&nbsp;C.E. Heilig ,&nbsp;D. Hübschmann ,&nbsp;S. Fröhling ,&nbsp;B.C. Köhler","doi":"10.1016/j.esmoop.2026.106082","DOIUrl":"10.1016/j.esmoop.2026.106082","url":null,"abstract":"<div><h3>Background</h3><div>International guidelines recommend molecular profiling for patients with advanced biliary tract cancer (BTC) eligible for systemic treatment, but the utility of deep, multi-omic approaches remains underexplored.</div></div><div><h3>Materials and methods</h3><div>We report molecular and clinical results of patients with BTC and enrolled in the German Cancer Consortium (DKTK) Molecularly Aided Stratification for Tumor Eradication Research (MASTER) program between February 2014 and December 2021. Tumor whole-genome/whole-exome (WGS/WES) and RNA sequencing (RNAseq) were carried out according to MASTER’s standardized workflow, and eligibility for molecularly informed therapies was discussed within MASTER’s molecular tumor board. Treatments included strategies based on a composite homologous recombination deficiency (HRD) biomarker (TOP-ART score) or RNAseq-based findings (gene fusions/overexpression).</div></div><div><h3>Results</h3><div>Among 131 registered patients, genomic and transcriptomic profiling were successful in 115 (89%) and 89 (77%) cases, respectively. Comparative evaluation of molecular profiles highlighted ultra-rare distinctive features of BTC, including an enrichment of <em>PTPRM</em> gene fusions. MASTER-informed therapy was implemented in 23 (20.0%) patients, of whom 4 were treated according to the TOP-ART score while 12 according to RNAseq-based recommendations (gene fusions and/or overexpression), including 1 case with a <em>MET</em> fusion. Median progression-free survival (PFS) on molecularly informed therapy was 4.6 (3.7-12.7) months, with a PFS ratio (δ &gt; 1.3)-based benefit rate of 60%.</div></div><div><h3>Conclusions</h3><div>Multi-omic profiling of BTC within the MASTER program uncovered novel therapeutic opportunities. By the identification of ultra-rare and composite biomarkers, MASTER-guided therapies resulted in clinical benefit also in heavily pretreated patients.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 5","pages":"Article 106082"},"PeriodicalIF":8.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147852043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors","authors":"L.L. Siu ,&nbsp;M.E. Gutierrez ,&nbsp;L. Pudelko ,&nbsp;K. Ruth ,&nbsp;M.A.F.N. Filho ,&nbsp;R. Zaynagetdinov ,&nbsp;P. Hu ,&nbsp;T. Kitzing ,&nbsp;B.K. Guenhan ,&nbsp;I. Durutovic ,&nbsp;M. McKean","doi":"10.1016/j.esmoop.2026.106962","DOIUrl":"10.1016/j.esmoop.2026.106962","url":null,"abstract":"<div><h3>Background</h3><div>Adenosine is a key driver of an immunosuppressive tumor microenvironment. Elevated extracellular adenosine levels in the tumor microenvironment contribute to therapeutic resistance via A₂_A and A₂_B adenosine receptor signaling on T cells. Dual A₂_A/A₂_B antagonism may provide a therapeutic advantage compared with selective inhibition of either receptor alone. Muvadenant (M1069), a small molecule dual antagonist of A₂_A and A₂_B receptors, showed encouraging preclinical activity.</div></div><div><h3>Patients and methods</h3><div>This phase I, open-label, first-in-human study (NCT05198349) evaluated muvadenant in adult patients with advanced solid malignancies (Eastern Cooperative Oncology Group performance status ≤1). Primary objectives were determination of maximum tolerated dose and recommended dose for expansion of muvadenant. Additional objectives included pharmacokinetics, pharmacodynamics and early signs of efficacy.</div></div><div><h3>Results</h3><div>Overall, 15 patients were evaluated across four dose levels (DLs) of muvadenant monotherapy provided twice daily (bd): 150 mg (<em>n</em> = 3), 300 mg (<em>n</em> = 3), 450 mg (<em>n</em> = 6), and 600 mg (<em>n</em> = 3). Dose-limiting toxicities were reported in two patients [grade 4 blood creatinine phosphokinase increased (450-mg DL, <em>n</em> = 1) and grade 3 lipase increased (600-mg DL, <em>n</em> = 1)]. Fatigue and nausea were the most common adverse events (<em>n</em> = 5 each, 33.3% each), while nausea was the most common muvadenant-related adverse event (<em>n</em> = 4, 26.7%). Two deaths were reported, both attributed to disease progression &gt;30 days after treatment end. Best overall response of stable disease was recorded in three patients, including one patient with a stable disease of 12.6 months at the 150-mg DL. Median progression-free survival was 1.3 months (95% confidence interval 1.2-2.6). The potential recommended dose for expansion was 450-mg bd, and the maximum tolerated dose was not established due to early closure of the study.</div></div><div><h3>Conclusions</h3><div>Muvadenant was generally well tolerated; however, no antitumor activity was observed. A potential dose–response could not be determined due to limited number of patients per DL.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 5","pages":"Article 106962"},"PeriodicalIF":8.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147851972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial","authors":"E. Scarlato ,&nbsp;V. Merz ,&nbsp;S. Pietrobono ,&nbsp;S. Casalino ,&nbsp;A. Quinzii ,&nbsp;C. Zecchetto ,&nbsp;L. Mendo ,&nbsp;S. Giacomazzi ,&nbsp;A. Bonato ,&nbsp;V. De Vita ,&nbsp;G. Butturini ,&nbsp;R. Salvia ,&nbsp;D. Melisi","doi":"10.1016/j.esmoop.2026.106964","DOIUrl":"10.1016/j.esmoop.2026.106964","url":null,"abstract":"<div><h3>Background</h3><div>The optimal perioperative strategy for resectable pancreatic ductal adenocarcinoma (PDAC) remains undefined, and predictive biomarkers to guide treatment selection are lacking. The phase II nanoliposomal IrinoTecan with 5-fluorouracil, levofolinic acid and oxaliplatin in patients with Resectable pancreatic cancer (nITRO) trial showed the activity of perioperative NALIRIFOX in patients with resectable PDAC. Here, we report updated survival outcomes and translational analyses of this trial.</div></div><div><h3>Patients and methods</h3><div>Plasma levels of 25 cytokines were quantified via multiplex bead-based immunoassay. Germline whole-exome sequencing assessed variants in tumor suppression, DNA damage repair (DDR), and drug metabolism pathways. Five <em>in silico</em> tools re-evaluated variants of uncertain significance. Statistical correlations between circulating cytokines or germline pathogenic variants and clinical outcomes were determined.</div></div><div><h3>Results</h3><div>After a median follow-up of 50.2 months, the median overall survival (mOS) was 32 months in the intention-to-treat population and 48 months in patients who underwent resection. High baseline tumor necrosis factor-alpha (TNF-α) levels were consistently associated with reduced treatment response (<em>P</em> = 0.022), lower resection probability (<em>P</em> = 0.007), and shorter survival (<em>P</em> = 0.014). Germline pathogenic/predicted damaging variants in DDR or tumor suppressor genes (<em>g.Deficient</em>) were detected in 36.2% of patients and correlated with improved outcomes. Patients with combined <em>g.Deficient</em>/TNF-α–low status achieved the most favorable prognosis, with an mOS of 55 months and a 100% resection rate. <em>DPYD</em> c.496A&gt;G predicted both severe gastrointestinal toxicity and chemotherapy dose reductions.</div></div><div><h3>Conclusions</h3><div>Long-term results from the nITRO trial confirm the activity of perioperative NALIRIFOX in resectable PDAC. Inflammatory, genomic, and pharmacogenomic biomarkers strongly influenced treatment response, surgical eligibility, survival, and toxicity. Biomarker integration could enable more precise patient stratification and guide personalized perioperative strategies in PDAC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 5","pages":"Article 106964"},"PeriodicalIF":8.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of molecular-matched therapies in salivary gland cancer","authors":"J.A.M. Weijers ,&nbsp;N.J. van Ruitenbeek ,&nbsp;A.C.H. van Engen-van Grunsven ,&nbsp;C.M.L. Driessen ,&nbsp;L.A. Devriese ,&nbsp;M. Slingerland ,&nbsp;A. Hoeben ,&nbsp;S.F. Oosting ,&nbsp;W.H. Schreuder ,&nbsp;A. Sewnaik ,&nbsp;S. van Helvert ,&nbsp;J.A. Schalken ,&nbsp;G.W. Verhaegh ,&nbsp;C.M.L. van Herpen","doi":"10.1016/j.esmoop.2026.106961","DOIUrl":"10.1016/j.esmoop.2026.106961","url":null,"abstract":"<div><h3>Background</h3><div>Salivary gland cancer (SGC) is a rare cancer comprising over 20 subtypes. Although its molecular landscape is increasingly characterised, real-world data on molecular-matched therapies (MMTs) remain limited, and predictive biomarkers are needed.</div></div><div><h3>Patients and methods</h3><div>Since 2017, real-world data of patients with SGC attending the outpatient clinic at Radboud university medical center have been systematically collected. Best overall response to MMT was assessed per RECIST v1.1. Median progression-free survival (mPFS) was estimated using Kaplan–Meier statistics and compared between the molecular subgroups using the log-rank test.</div></div><div><h3>Results</h3><div>At data cutoff, the database contained 662 patients with SGC, including 464 patients with recurrent and/or metastatic disease. Among them, 381 patients exhibited ≥1 molecular alteration, of whom 54% received MMT. Among patients with salivary duct carcinoma (SDC), 83% of patients with ≥1 molecular alteration received MMT, compared with 25% with adenoid cystic carcinoma. In 110 patients with SDC, mPFS with any first-line androgen receptor axis–targeted therapy was 5.3 months [95% confidence interval (CI) 3.5-7.2 months] and was significantly longer in <em>HRAS</em>-mutant (19.1 months; 95% CI 11.0-27.2 months; <em>n</em> = 18) versus <em>HRAS</em>–wild-type cases (3.8 months; 95% CI 2.0-5.6 months; <em>n</em> = 64; <em>P</em> = 0.007). With the first human epidermal growth factor receptor 2-targeted therapy given (<em>n</em> = 35), mPFS was 8.5 months (95% CI 6.4-10.6 months), with objective responses in 61% of RECIST-assessable patients (<em>n</em> = 28). Additionally, objective responses were achieved with other MMTs, including vemurafenib/cobimetinib in <em>BRAF</em> V600E-mutant SDC (<em>n</em> = 3), larotrectinib in secretory carcinoma with <em>ETV6</em>::<em>NTRK3</em> gene fusions (<em>n</em> = 2), and ipilimumab/nivolumab in mucoepidermoid carcinoma with high tumour mutational burden (<em>n</em> = 1).</div></div><div><h3>Conclusions</h3><div>Comprehensive molecular testing in SGC may allow access to MMT, with a subset of patients experiencing clinical benefit from this strategy.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 5","pages":"Article 106961"},"PeriodicalIF":8.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147799819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"70P Cytokine patterns as potential predictive and prognostic immunotherapy biomarkers","authors":"A. Losurdo ,&nbsp;L. Zotti ,&nbsp;L. Giordano ,&nbsp;N. Gavioli ,&nbsp;F. Bruzzone ,&nbsp;A. Dipasquale ,&nbsp;P. Persico ,&nbsp;A. Di Muzio ,&nbsp;C. Barigazzi ,&nbsp;I. Tallarico ,&nbsp;A. Santoro ,&nbsp;R. Bonecchi ,&nbsp;M. Simonelli","doi":"10.1016/j.esmoop.2026.106211","DOIUrl":"10.1016/j.esmoop.2026.106211","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106211"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"52eP Correlation of tumor size with cellular isolate yield in serous ovarian cancer as a predictive factor for ATMP manufacturing in TIL therapy","authors":"Z. Usmial,&nbsp;M. Gutek,&nbsp;A. Biernacka,&nbsp;J. Marynowska","doi":"10.1016/j.esmoop.2026.106157","DOIUrl":"10.1016/j.esmoop.2026.106157","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106157"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"60O First-in-human phase I evaluation of HCB301, a tri-specific SIRPα-PD-1-TGFβ fusion protein: Safety, pharmacokinetics, and multisystem immune activation","authors":"J. Zhu ,&nbsp;W. Edenfield ,&nbsp;H. Tong ,&nbsp;L. Sun ,&nbsp;A. Liu ,&nbsp;X. Hu ,&nbsp;A. Yu ,&nbsp;F. Mo ,&nbsp;A. Luk","doi":"10.1016/j.esmoop.2026.106201","DOIUrl":"10.1016/j.esmoop.2026.106201","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106201"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"117P Targeted compound screening for the exploration of actionable vulnerabilities in LUSC","authors":"A.T. Iovita ,&nbsp;E. Isachesku ,&nbsp;O. Zanoaga ,&nbsp;L. Raduly ,&nbsp;L. Budisan ,&nbsp;C. Braicu ,&nbsp;C. Ciocan ,&nbsp;A.A. Tirpe ,&nbsp;S. Strilciuc ,&nbsp;A. Bender ,&nbsp;I. Berindan-Neagoe","doi":"10.1016/j.esmoop.2026.106258","DOIUrl":"10.1016/j.esmoop.2026.106258","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106258"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}